ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Gene expression and proteomic profile studies of CML LSCs drew attention to specific gene pathways that could represent both prognostic indicators as well as new targets for therapy that might eventually overcome resistance to the BCR-ABL TKIs [31, 32].